Immunic (IMUX) to Release Quarterly Earnings on Thursday

Immunic (NASDAQ:IMUX) is anticipated to post its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect Immunic to post earnings of ($0.22) per share for the quarter.

Immunic Trading Down 4.2 %

Shares of NASDAQ:IMUX opened at $1.15 on Wednesday. The firm has a fifty day moving average price of $1.03 and a 200 day moving average price of $1.25. Immunic has a 1 year low of $0.92 and a 1 year high of $2.11. The stock has a market capitalization of $103.59 million, a PE ratio of -0.93 and a beta of 1.87.

Wall Street Analyst Weigh In

A number of research firms have recently commented on IMUX. StockNews.com lowered shares of Immunic from a “hold” rating to a “sell” rating in a research report on Saturday. D. Boral Capital reissued a “buy” rating and set a $17.00 price objective on shares of Immunic in a research report on Thursday, February 20th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Immunic in a research report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, six have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $12.67.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.